ChemoMetec's Strategic Revenue Guidance for Financial Year 2025/26

Author: Logan Wright Updated: 09-11-2025 01:15 PM

ChemoMetec's Guidance for the Upcoming Financial Year

ChemoMetec has recently announced its financial guidance for the 2025/26 financial year, a significant development for stakeholders and investors alike.

Projected Revenue and EBITDA

In the forthcoming financial year, ChemoMetec anticipates revenues reaching between DKK 545 million and DKK 565 million. This marks a noticeable increase from the previous financial year's revenue of DKK 495.6 million. Moreover, the company expects its EBITDA to be in the range of DKK 295 million to DKK 315 million, compared to DKK 258 million the prior year.

Understanding the Guidance Parameters

The guidance provided by ChemoMetec is based on detailed assumptions and insights outlined in its annual report for 2024/25. This report serves not only to present financial results but also to clarify the rationale and projections for the future. Investors and analysts can gain a better understanding of the factors influencing these expectations by reviewing the relevant pages in the report.

Company Overview and Market Position

Founded in 1997, ChemoMetec A/S has carved a niche in developing and manufacturing state-of-the-art instruments designed for cell counting and various measurements. The company has established a robust presence in multiple sectors, including pharmaceuticals, biotech, and agriculture, catering to some of the leading pharmaceutical giants globally.

Leadership and Contact Information

The leadership at ChemoMetec plays a pivotal role in guiding the company through its financial and operational strategies. Martin Helbo Behrens serves as the CEO, while Kim Nicolajsen holds the position of CFO. For inquiries, stakeholders can reach them at (+45) 48 13 10 20.

Commitment to Innovation and Quality

ChemoMetec places a strong emphasis on quality and innovation, continuously striving to enhance its product offerings. The company’s commitment to research and development ensures that it stays at the forefront of technological advancements within its industry.

Frequently Asked Questions

What is ChemoMetec's expected revenue for the 2025/26 financial year?

ChemoMetec expects its revenue to be between DKK 545 million and DKK 565 million for the financial year 2025/26.

How does the projected EBITDA compare to the previous year?

The projected EBITDA for 2025/26 ranges from DKK 295 million to DKK 315 million, which is an increase from DKK 258 million in 2024/25.

Where can I find more information about ChemoMetec?

For more information, you can visit ChemoMetec's official website at www.chemometec.com.

Who are the key figures in ChemoMetec's leadership?

The key figures in ChemoMetec's leadership are Martin Helbo Behrens, the CEO, and Kim Nicolajsen, the CFO.

In which industries does ChemoMetec operate?

ChemoMetec operates in the pharmaceutical, biotech, and agricultural industries, providing advanced instruments for cell counting and other measurements.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.